ISSN:
1432-0843
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Adriamycin, a broad-spectrum cytotoxic agent useful in cancer chemotherapy, is limited by a dose-dependent cardiomyopathy mediated in part by disruption of mitochondrial energetics. Hexakis(2-methoxyisobutyl isonitrile)technetium(I)(99mTc-SESTAMIBI) is a gammaemitting radiopharmaceutical with myocellular accumulation properties dependent on mitochondrial membrane potential. To test the hypothesis that99mTc-SESTAMIBI could monitor Adriamycin-induced alterations in cardiac energetics, cultured chick heart cells were treated with Adriamycin and99mTc-SESTAMIBI tracer kinetics were determined. Concentration- and time-dependent depression of99mTc-SESTAMIBI accumulation was evident within 60 min of treatment. The apparentK i for acute Adriamycin inhibition of tracer accumulation was 82 μM. After 24 h of treatment, Adriamycin concentrations as low as 0.1 μM demonstrated detectable inhibitory effects. The apparentK i for this subchronic Adriamycin inhibition of99mTc-SESTAMIBI accumulation was 18 μM. Subchronic concentration-dependent increases in adriamycin-induced myocellular injury as reflected by lactate dehydrogenase (LDH) release correlated inversely with decreases in99mTc-SESTAMIBI accumulation. These data further support a contribution from altered mitochondrial energetics to Adriamycin-induced injury and establish a pharmacological foundation for pursuing the possibility of noninvasive imaging of chronic Adriamycin cardiotoxicity in cancer patients using99mTc-SESTAMIBI.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00735924
Permalink